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This overview focuses on the (a,a-difluoromethylene)phosphonatemimic of phosphoserine (pCF2Ser) and its
application to the study of kinase-mediated signal transduction—pathways of great interest to drug develop-
ment. The most versatile modes of access to these chemical biological tools are discussed, organized by
method of PCF2-C bond formation. The pCF2-Ser mimic may be site-specifically incorporated into peptides
(SPPS) and proteins (expressed protein ligation). This isopolar, dianionic pSer mimic results in a ‘‘constitutive
phosphorylation’’ phenotype and is seen to support native protein-protein interactions that depend on serine
phosphorylation. Signal transduction pathways studied with this chemical biological approach include the
regulation of p53 tumor suppressor protein activity and of melatonin production. Given these successes,
the future is bright for the use of such ‘‘teflon phospho-amino acid mimics’’ to map kinase-based signaling
pathways.Introduction
It has long been known that biological macromolecules undergo
kinase-mediated phosphorylation. The reverse step, dephos-
phorylation, is also usually phosphatase-controlled. Perhaps
because the phosphorylation event itself greatly changes the
charge distribution and polarity of the substrate, it is often asso-
ciated with signal transduction/amplification. This is particularly
the case for sequence-specific phosphorylations on the amino
acid side chains of serine, threonine, and tyrosine. The bcr-abl
kinase was the first of several to be successfully targeted in
cancer therapeutic drug development, resulting in FDA approval
of the drug Gleevec (Imatinib) in 2001. As of this writing, no fewer
than eight kinase inhibitors are on the market for cancer chemo-
therapy (Boros and Boros, 2007; Pytel et al., 2009), and some
150 kinase inhibitors are in clinical trials (Savage and Gingrich,
2009). As such, the elucidation of kinase/phosphatase-con-
trolled signal transduction pathways has emerged as one of
the most important front end tasks in the medicinal chemistry
arena.
Bioorganic chemists have long sought to develop functional-
ities that effectively mimic biologically relevant phosphate
esters, yet remain inert to phosphatase cleavage. This research
domain resembles the peptidomimetics field, in that one seeks
to build new organic functional groups that retain key properties
of the native structure, yet resist enzymatic biodegradation.
Interestingly, organically bound fluorine has played an important
role in both endeavors, surely bolstered by polarity afforded by
fluorine in compensating for lost oxygen atoms. For example, flu-
oroalkenes, in which the electronegative fluorine atom replaces
the carbonyl oxygen, can serve as viable peptide isosteres
(Welch, 2008). The strength of C-F bonds (O’Hagan, 2008),
and their ability to impose unique conformational constraints
(Gorres et al., 2008; Nieschalk et al., 1996) are important
elements that support such designs. Moreover, the addition of928 Chemistry & Biology 16, September 25, 2009 ª2009 Elsevier Ltmultiple C-F bonds can increase stability to chemical oxidation
(DiMagno et al., 1996) and metabolism, and provide additional
driving force to enhance binding with macromolecular targets,
in aqueous solution (Biffinger et al., 2004).
Dating back to key early reports from the groups of Blackburn
(Blackburn et al., 1981), McKenna (McKenna and Shen, 1981),
and Burton (Burton and Flynn, 1982) on pyrophosphate mimics
in the 1980s, there has emerged an interest in synthesizing
a-fluorinated phosphonates as potentially isopolar analogs
(Blackburn et al., 1985b) of the corresponding phosphate esters.
This has spurred a great effort in methodology development
in this area (Benayoud et al., 1996; Blackburn et al., 1985a;
Blackburn et al., 1994; Blades et al., 1997; Caplan et al., 2000;
Cockerill et al., 2000; Diab et al., 2008; Gautier et al., 2004; Her-
pin et al., 1996; Hikishima et al., 2006; Lopin et al., 2003; Murano
et al., 2005; Nair and Burton, 1997; Ozouf et al., 2004; Pajkert
et al., 2008; Pfund et al., 2005; Pignard et al., 2006; Roe-
schenthaler et al., 2006; Xu et al., 2005; Yokomatsu et al.,
2003). The phosphate mimics program in this laboratory was
initiated around the goal of establishing methods to access fluo-
rinated phosphonate analogs of sugar phosphates (Berkowitz
et al., 2001; Berkowitz et al., 2000a; Berkowitz et al., 1993;
Shen et al., 1994), and continues in this direction, with a particular
interest, of late, in bivalent sugar phosphonates as ligands for the
mannose 6-phosphate-insulin-like growth factor II receptor
(M6P/IGF2R) (Berkowitz et al., 2004; Fei et al., 2008).
Although phosphorylations at threonine (Di Croce and Shie-
khattar, 2008; Kulasekara andMiller, 2007), andcertainly tyrosine
(Franco and Tamagnone, 2008; Girault, 2006; Grangeasse et al.,
2007; Nag and Chaudhary, 2009; Roskoski, 2008; Zhang et al.,
2009), are of great importance, this overview focuses on serine
phosphorylation. (For nice complementary discussions from the
groups of Otaka and Ojea, primarily focusing on the chemistry
of other phosphono-AAs, see Fernandez et al., 2006; Otakad All rights reserved
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examine the use of the (a,a-difluoromethylene)phosphonate
functionality to mimic the phosphate monoester form of serine
residues, in proteins that are subject to regulation via serine
phosphorylation. The archetypical example of such a system is
represented by the complex interplay of the enzymes glycogen
phosphorylase (GP; catabolism) and glycogen synthase (GS;
anabolism), cascades associated with glycogen metabolism.
These enzymes are each tightly controlled via kinase/phospha-
tase enzymes that respond to hormonal signals from epinephrine
or insulin. For example, epinephrine binding to its cognate
receptor results in the activation of adenylate cyclase (Sunahara
et al., 1996), and the formation of cAMP, the ‘‘universal second
messenger.’’ This leads to the activation of cAMP-dependent
protein kinase A, which, in turn, activates phosphorylase kinase,
which itself activates glycogen phosphorylase, both activations
occurring via enzymatic phosphorylations at serine residues
(Toole and Cohen, 2007).
It now appears that the principal phosphorylations are at
Ser-14 in GP and at Ser-7 and Ser-640 in GS (Toole and Cohen,
2007). However, the complexity of kinase-phosphatase regula-
tion of this key metabolic branch point is remarkable. For
example, in GS alone, nine serine residues can be phosphory-
lated by regulatory kinases, leading to a theoretical complexity
of 512 combinations of distinct Ser/pSer patterns, each poten-
tially with a different kinetic profile. Fortunately, as a result of
hierarchal phosphorylation, the number of configurations of GS
observed is considerably lower. The group of Jensen has pains-
takingly set about to identify and kinetically characterize the
most important ‘‘phospho-forms’’ of this enzyme (Jensen and
Lai, 2009).
Synthesis of the pCF2-Ser Phosphoserine Mimic
It occurred to us and others that for the study of such signal
transduction pathways, it would be useful to have available
a stable mimic of the phosphorylated form of the enzyme.
Indeed, this led us to develop the first synthesis of the CF2-phos-
phonate mimic of pSer, in a form suitable for automated peptide
synthesis, 15 years ago. Actually, both our first-generation and
second-generation synthesis, starting from L-serine and (R)-iso-
propylideneglycerol, respectively, were disclosed in that first
communication (Figures 1 and 2) (Berkowitz et al., 1994b). In
the following year, the groups of Otaka and Burke collaboratively
reported a complementary approach to the same target (Otaka
et al., 1995a). In what follows, these syntheses are organized
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Figure 1. PCF2-C Bond Formation via Triflate Displacement—
Stereocontrol via Chiron Approach from L-SerineChemistry & Biologyaccording to PCF2-C bond disconnection, and they are pre-
sented along with several more recent approaches, to provide
the medicinal chemist with an overview of the routes available
to synthesize this ‘‘teflon pSer mimic.’’ This is followed by a
look at elegant studies, by the groups of Appella and Cole,
respectively, on using this pSer mimic to examine the role of
serine phosphorylation in signal transduction.
In Figure 1 is presented our first-generation approach to the
pCF2-Ser building block for peptide synthesis. A chiron
approach was taken, emanating from L-serine. As alluded to
earlier, an important observation had been made in our labora-
tory that informed our thinking about (a,a-difluoromethylene)-
phosphonate synthesis. Namely, in early work by Blackburn
and coworkers, it was observed that the LiCF2P(O)(OEt)2 anion
is unstable to a-elimination to difluorocarbene, at temperatures
of approximately40Cor higher (Blackburn et al., 1987). There-
fore, we sought to develop especially efficient ways of capturing
this nucleophile, at low temperatures. Indeed, it was found
that displacements of primary sugar triflates generally proceed
at 78C with this reagent, in a matter of minutes (Berkowitz
et al., 1993). This behavior contrasted sharply with the markedly
lower reactivity of alkyl halides.
In seeking to apply the triflate displacement approach to the
synthesis of the pSer mimic, we were confronted with an issue
of functional group cross-compatibility. Namely, would it be
possible to carry a masked amino group into the triflate scaffold
itself, so that the synthesis could commence with L-serine itself?
In fact, the challenge was much greater. Because of the densely
functionalized serine framework, the desired pCF2-Ser synthon
was to possess an a-triflyloxy, (protected)-b-amino substructure
(Figure 1). It was found that mono-protection of the amine, even
with strongly electron-withdrawing N-sulfonyl functionality, did
not lead to manageable triflates, perhaps because of neigh-
boring group participation (possible aziridinium ion formation).
Thus, bis-protection of the neighboring nitrogen, (i) as an acyclic
Bn-N-Ts group, (ii) through incorporation into a 2,5-dimethylpyr-
role group, or (iii) through cyclization to the oxazolidinone (as in
Figure 2), and N-benzylation, all led to primary triflates that
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Reviewwere stable to chromatography and could be displaced by
LiCF2P(O)(OEt)2. However, in all cases, N-deprotection, in the
presence of the resultant fluorinated phosphonate, proved prob-
lematic. A solution was found with the latter protection scheme,
wherein the N-benzyl protecting group was replaced with a
much more labile N-TBS blocking group.
The N-protecting group problem that emerged in this first-
generation route resulted in a longer synthesis than envisioned,
that also suffered from suboptimal N-deprotection conditions.
Namely, introduction of the N-BOC functionality serves the
dual purpose of activating the oxazolidinone for ring opening
and installing a protecting group appropriate for peptide
synthesis. Unfortunately, that ring opening proceeds in modest
yield and limits the efficiency of this route. So, the phosphonate
team in the laboratory set about on a parallel route, in which
triflate displacement would still be employed for fluorinated
phosphonate installation, but on a glyceryl acetonide scaffold,
rather similar to the sugar scaffolds originally employed
(Berkowitz et al., 1993). This worked smoothly and allowed for
late introduction of nitrogen, via azide displacement upon
a secondary triflate (Figure 2). This remains a rather streamlined
and underused route into the pCF2-Ser target. Chemical biolo-
gists active in this field are encouraged to examine this isopropy-
lidineglycerol route, if in need of a clean rapid entry into this
phosphono-peptide building block.
Indeed, highlighting the practicality of this type of approach,
the efforts of a phosphonate group in Tokyo, under Shibuya
(Yokomatsu et al., 1996), resulted in a conceptually different
approach to stereocontrol, while retaining the same sort of
triflate displacement chemistry as had been employed in our
second-generation synthesis (Figure 3). Cleverly, Yokomatsu
et al. utilized the mono-acetonide of the C3v-symmetrical tris
(hydroxymethyl)methane (THYM) starting material as triflate
precursor. Triflate displacement proceeds smoothly. This is fol-
lowed by acetonide cleavage to produce a 1,3-diol that may
be efficiently desymmetrized with several lipases. Note that
enzymatic desymmetrization is, of course, an excellent strategy
for achieving both high ee and high throughput. The strategy is
exceedingly efficient here, and, in our own experience, can be
employed with advanced meso intermediates (Berkowitz et al.,
2000b; Berkowitz et al., 1996b), relatively deep into total
synthetic ventures, particularly with lipase enzymes. Second,
we have also found that lipase-mediated hydroxymethyl arm
acylation is a very effective strategy for chiral discrimination for
unnatural amino acids. This approach works, even for quater-
nary amino acid synthons, after reduction of the a-carboxyl to
a hydroxymethyl group (Berkowitz et al., 1994a).
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Figure 3. Shibuya Route: PCF2-C Bond
Formation via Triflate Displacement—
Enzymatic Desymmetrization
Also in this case, N-introduction occurs
late in the synthesis, but via Curtius
rearrangement, instead of triflate dis-
placement. The Tokyo route and our
second-generation triflate displacement
route also share the advantage of permit-
ting N-carbamate deprotection, in situ, though in different ways.
Interestingly, since the original Shibuya route was published,
studies by Guanti and coworkers (Banfi and Guanti, 1998;
Banf et al., 2005), in particular, have produced a number of
methods for tris(hydroxymethyl)methane desymmetrization.
So, one should be able to enter this triflate displacement route
with a single antipode of this type of THYM educt. The resulting
phosphonate would possess differentially protected hydroxy-
methyl arms, streamlining the Tokyo route even further.
All of the aforementioned triflate displacement-based chem-
istry was carried with diethyl protection across the fluorinated
phosphonate moiety, as this is the most well studied synthon.
It is worthy of note that we have developed complementary
fluorinated phosphonate reagents, carrying both dibenzyl (Ber-
kowitz et al., 1999) and diallyl (Berkowitz and Sloss, 1995) phos-
phonate protection. Both reagents have performed well in model
triflate displacement studies and may, in the future, allow for
adaptation of these routes to the synthesis of pCF2-Ser mono-
mers bearing more convenient side chain protecting groups.
Figure 4 highlights a route developed jointly by Kawamoto and
Campbell (1997) that features transition metal-mediated alkene
addition of (RO)2P(O)CH2ZnBr, similar to a reaction developed
by Burton, under both Pd and Cu-catalysis (Yang and Burton,
1992). More recently, related transformations have been devel-
oped in the thiono series by Piettre and colleagues (Lequeux
et al., 2001; Pignard et al., 2006). These latter reactions do not
require transition metal catalysis and are routinely run under
radical chain conditions. Following (RO)2P(O)CF2-radical addi-
tion to a-bromoacrylate, nitrogen is introduced late via bromide
displacement. Stereocontrol comes still later, through a classical
resolution, via chromatographic separation of the diastereo-
meric bornyl esters.
Lastly, the original Otaka route (Figure 5) features a third
method of fashioning the PCF2-C linkage, namely via (RO)2
P(O)CF2Li addition to carbonyl centers (Otaka et al., 1995a;
Otaka et al., 1995b). Specifically, the Kyoto group utilizes the
Garner aldehyde (Garner andPark, 1992) andemploys acarbonyl
addition/Barton ester-type deoxygenation sequence, similar to
that described by Martin and coworkers, in non-AA contexts
(Martin et al., 1992). Our own carbonyl addition route (Berkowitz
et al., 1996a) utilizes the Garner ester as electrophile and, by
design, allows the experimentalist to assess three different
L-(a,a-difluoromethylene)phosphono AAs, the analogs of pSer,
p-allo-Thr, and pThr, from a common, b-keto-a,a-difluoro-
phosphonate intermediate, by treatment either with LiBH4 or
withMeMgBr, prior to deoxygenation. As can be seen in Figure 5,
if one only wishes to synthesize the pCF2-Ser mimic, the two
930 Chemistry & Biology 16, September 25, 2009 ª2009 Elsevier Ltd All rights reserved
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Reviewroutes are very similar (Corey-Schmidt [PDC-DMF] oxidation
versus RuO4 in final step). Because of the ready accessibility of
the Garner ester, this route appears to be the most widely
used. The fact that it also provides access to the individual
L-phosphonothreonine diastereomers makes this a versatile
approach.
Use of the pCF2-Ser Mimic as a Tool for the Study
of Signal Transduction
The p53 protein is a tightly regulated tumor suppressor protein
(Sherr, 2004), mutated in 50% of human cancers (Bykov et al.,
2002; Toledo and Wahl, 2006). The p53 protein, when activated,
dissociates from its mdm2 (hdm2 is the human equivalent)
binding partner, undergoes conformational change, and acts as
a transcription factor, typically leading to either cell cycle arrest
or apoptosis (Liebermann et al., 2007). Both appear to be
protection mechanisms, especially with the finding that tumor
senescence may be associated with inflammatory cytokine
up-regulation and tumor clearance (Xue et al., 2007). Activation
of p53 occurs in response to cellular stress signals, including
DNA damage, osmotic shock (Kishi et al., 2001), oxidative stress
(Han et al., 2008), and hyperglycemia. Conversion of the latent
form of p53 to its active transcription factor form appears to
involve initial phosphorylation (primarily at N-terminal serines)
and subsequent acetylation (C-terminal lysines- K320 andK382).
Several experiments underscore the importance of under-
standing p53 function and regulation, especially for medicinal
chemistry programs in the oncology (Bell and Ryan, 2007; Haupt
and Haupt, 2006; Vassilev, 2005) and diabetes areas (Fiordaliso
et al., 2001). Jacks and coworkers developed a clever genetic
construct for temporal control of p53 expression (Ventura
et al., 2007). Initially, p53 was held genetically latent and could
be restored via a Cre recombinase mechanism. Restoration of
p53 function was shown to lead to tumor regression, with the
effect dependent on tumor type. This work pointed to the impor-
tance of altered p53 function in tumorigenesis and tumor main-
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Figure 4. Kawamoto-Campbell-Burton Route: PCF2-C Bond
Formation via Cu-Mediated Conjugate Addition-Resolution of
Borneol EstersChemistry & Biologytenance. This genetic system, then, serves as a model for phar-
macological reactivation of p53. Indeed, along those lines,
a couple of interesting early small molecule modulation experi-
ments have come to the fore. For example, small molecules
capable of both restoring transcriptional activation function to
p53 mutants (Bykov et al., 2002) and of inhibiting p53-mdm2
interactions (Vassilev et al., 2004) have been described, each
avenue representing a fundamentally new approach to cancer
chemotherapy, if viable.
Given the prevalence of p53 abnormalities in cancer and the
importance of serine phosphorylation in its regulation, there
has been a very high level of interest in the study of kinase-regu-
lated signal transduction in this system. Among the candidate
sites for p53 modulation, via phosphorylation, are included
S-6, S-9, S-15, T-18, S-20, S-33, S-37, and S-46 at the
N-terminus, as well as S-315 and S-392 at the C terminus.
In terms of regulatory complexity, at the level of serine phosphor-
ylation, this system, then, is reminiscent of the glycogen
phosphorylase/glycogen synthase pair discussed earlier. Inter-
estingly, at the C terminus of p53, O-glycosylation may be in
direct competition with O-phosphorylation (Clarke et al., 2008;
Haltiwanger et al., 1997; Hart et al., 1995; Wells et al., 2003),
with the former being particularly important in cases of hypergly-
cemia (Fiordaliso et al., 2001).
From a chemical biology point of view, one way of examining
the effects of posttranslational modifications, is to engineer
functional variants that model both the ‘‘switched on’’ and
‘‘switched off’’ states of the macromolecule. Although it is easy
to genetically engineer ‘‘constitutively dephosphorylated’’ sites
by mutating phosphorylation site Ser residues to Ala residues,
and this has been shown to be quite effective in the p53 system
(Yamauchi et al., 2004), the reverse mutation is unavailable by
standard molecular biological techniques, because Asp or Glu
are often unsuitable mimics of pSer (Zheng et al., 2003), and
there are no better choices available among the proteinogenic
AAs. The incorporation of a phosphatase-inert pSer mimic
C
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Reviewposition-specifically into a protein of interest is now possible with
expressed protein ligation (EPL) techniques. Moreover, in such
endeavors, it appears to be especially advantageous to use
phosphono-AA mimics in which a CF2 (as opposed to a CH2)
replaces the bridging ester oxygen (Zhang et al., 2003). Among
the possible reasons for this advantage is the aforementioned
‘‘isopolarity’’ of the CF2 unit with the native bridging O. However,
pKa effects may be even more important. The simple CH2-phos-
phono analog of pSer is expected to have pKa2 of 7–8, whereas
its CF2-phosphono counterpart typically displays pKa2 under 6,
depending upon molecular context (Berkowitz and Bose, 2001;
Berkowitz et al., 2000a; Blackburn et al., 1984). Thus, both the
native pSer residue and the pCF2-Ser mimic will present as
almost exclusively dianionic side chain modifications under
most conditions. This ability to bring in such a chemically tuned,
hydrolytically stable, pSer mimic, using EPL techniques, will be
discussed below, in the context of recent studies of melatonin
regulation.
In the p53 area, the most common modus operandi for
studying site-specific phosphorylation itself—that is, for running
‘‘phosphorylation-positive’’ experiments—is a reactive one,
rather than a proactive one. That is to say, rather than effectively
generate ‘‘constitutive’’ pSer sites in p53 and examine functional
responses to these, one looks at the pSer profile of p53 in
response to a stimulus. The analytical tools needed for such
studies are a set of antibodies (Abs) for site-specific phosphory-
lation variants of p53. For p53, activation usually involves
serine phosphorylation, with sites available at both the N- and
C-terminal regions.
A precedent-setting study in antibody-based mapping tech-
nology was carried out by Appella and coworkers at the NIH
(Higashimoto et al., 2001; Higashimoto et al., 2000) (Figure 6).
The group sought to specifically examine phosphorylation at
Ser-6 and Ser-9 in p53, in response to DNA damage. It was
found that one could successfully raise Abs against pSer-9-
containing peptide-KLH-protein conjugate and that these
Abs, in turn, effectively recognized p53 protein that was specif-
ically phosphorylated at Ser-9. However, the same procedure
for producing pSer-6-complementary Abs failed. Abs were
obtained, but these recognized only p53 samples presenting
an unphosphorylated Ser-6-site. It appears that the peptidyl-
KLH conjugate suffered phosphatase-mediated Ser-6-O-phos-
phate cleavage in the rabbit immunization step.
Appella’s teamastutely recognized that the use of an ‘‘isosteric
and isopolar’’ (Blackburn et al., 1985b;Blackburn et al., 1981), yet
hydrolytically stable, pSer mimic might overcome this, otherwise
apparently insurmountable, barrier. As is depicted in the Figure 6,
the pCF2-Ser mimic, indeed, served this purpose exceptionally
well, producing high titers of Ab that recognized only pSer-6-
posttranslationallymodified (PTM) p53 samples. This experiment
demonstrates, at once, the utility of this phosphoserine mimic
for overcoming phosphatase cleavage and its ability to quite
accurately mimic the size, polarity, and charge distribution of
the native PTM. After all, the raised Ab was ‘‘remodeled’’ against
the pSer surrogate and deployed against actual, pSer-modified
p53, and showed complete fidelity in recognizing the true
functionality.
Using this chemical biological tool, the Appella groupwas able
to establish that Ser-6 is phosphorylated in response to DNA932 Chemistry & Biology 16, September 25, 2009 ª2009 Elsevier Ltdamage induced by both UV light and ionizing radiation (Higashi-
moto et al., 2000). In subsequent studies, an unexpected
interdependence was seen between Ser-6 and Ser-9 phosphor-
ylation (Saito et al., 2003). That is, in the absence of Ser-9 (S9A
mutant), no phosphorylation is seen at Ser-6, and vice versa.
This work established that the N-terminal transactivation domain
of p53 appears to be divisible into four clusters of interdependent
serine residues, from the point of view of phosphorylation. This
site interdependency model is seen as a mechanism for both
control and signal amplification.
As alluded to in the previous discussion, it would be evenmore
powerful if one could generate phosphorylation ‘‘knock-in’’
mutants to complement the phosphorylation ‘‘knock-out’’
mutants typically constructed by Ser to Ala mutations. This
would allow one to go beyond analyzing phosphorylation
patterns that are generated by native kinases. Rather, one would
be generating artificially a ‘‘constitutive phosphorylation signal’’
and examining the downstream consequences of that signal
transduction event.
In Figure 7 is illustrated a seminal study by the group of Philip
Cole at Johns Hopkins that uses the power of EPL to surgically
insert the pCF2-Ser mimic of pSer into a protein, at a site of
interest (Zheng et al., 2005). The EPL technique (Muir et al.,
1998; Schwarzer and Cole, 2005) involves coupling intein tech-
nology to cysteine ligation methodology inherent in the parent
native chemical ligation procedure (Dawson et al., 1994). EPL
may be regarded as the state of the art for chemical biological
manipulation of side chain functionality, and is especially useful
for studying PTMs and their relation to signal transduction
(Flavell and Muir, 2009; Pickin et al., 2008; Rauh and Waldmann,
2007).
In the case at hand, Cole and co-workers were interested in
examining closely the regulation of arylalkylamine N-acetyltrans-
ferase (AANAT), an enzyme that catalyzes the penultimate step
in the biosynthesis of the time-keeping hormone, melatonin
(Klein, 2007). Melatonin, N-acetyl-50-methoxytryptamine, is bio-
synthesized by the decarboxylation of 50-hydroxytryptophan to
serotonin, followed by N-acylation and O-methylation. It is the
N-acylation step that is mediated by AANAT, with acetyl-CoA
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Reviewserving as acyl donor. It had been surmised that phosphorylation
at Thr-31, and potentially Ser-205, modulated in vivo acyltrans-
ferase activity. Two mechanisms for this effect were in play: (i)
improving the catalytic efficiency for the acyl transfer reaction
and (ii) increasing the biological half-life of AANAT enzyme.
Themechanism for AANAT stabilization is an interesting one—
namely, the protein is thought to be shielded from proteosomal
proteolysis by association with a specific14-3-3 adaptor protein,
the zeta-variant. Over 100 signaling proteins have been reported
to bind to 14-3-3 proteins, and these interactions are typically
associated with pSer or pThr modifications on the signaling
protein (Klein et al., 2003; Obsil et al., 2001; Tzivion and Avruch,
2002). In the case at hand, in the dark, AANAT activity and
protein levels increase. The putative activating phosphorylations
are thought to be mediated by protein kinase A, in response to
elevated cAMP levels, in the pineal gland, as a result of a1 or
b-adrenergic receptor activation. Thus, through EPL with the title
pSer mimic, the Cole group sought to engineer in ‘‘constitutive
phosphorylation’’ at position-205 and to test for positive interac-
tion between AANAT and its 14-3-3-zeta partner.
In the Hopkins experiment, the requisite octapeptide for EPL
was synthesized by standard solid phase peptide synthesis
(SPPS). The sequence represents a modified C terminus, in that
the Ser residue normally at position 205 was replaced by the
pCF2-Ser mimic, and a Cys residue was installed in place of
the native Ala-200, to enable the cysteine-mediated acyl transfer
chemistry that underlies the ligation chemistry in EPL. On the
other end, the AANAT protein itself was expressed as a comple-
mentary C-terminal (8-) truncated-intein-CBD (chitin-binding
domain) fusion construct. The CBD allowed for facile purification
via affinity chromatography. The tag could then be clipped by
trans-thio-esterificationwith b-mercaptoethanesulfonate, setting
the stage for ligation. Incubation of the synthetic, N-Cys-termi-
nated, (a,a,-difluoromethylene)phosphono-peptide proceeded
cleanly, presumably via the usual two stage, intermolecular
trans-thio-esterification/intramolecular S-N acyl transfer mecha-
nism, providing the targeted semisynthetic protein (Figure 7).
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Using this construct, the Cole group was able to
demonstrate clearly that Ser-205 phosphorylation,
though at the C terminus and not a part of a recog-
nized 14-3-3-zeta consensus sequence, enhances
cellular stability of the AANAT protein. Subsequent
studies showed that this effect persists in live cells,
expanding the domain in which such ‘‘teflon phos-
phates’’ may be deployed to ask fundamental
questions in chemical biology (Zheng et al., 2005;
Szewczuk et al., 2008). Interestingly, from this latter
study, it was confirmed that, surprisingly, Ser-205
phosphorylation on AANAT confers a greater
binding affinity for 14-3-3-zeta (0.86 mM Kd) than
does Thr-31 phosphorylation (1.8 mM Kd). On the
other hand, the latter PTM alone improves the cata-
lytic efficiency (kcat/Km) of the acyl transferase by
approximately seven fold, largely by decreasing the Km for sero-
tonin. However, that catalytic improvement is essentially lost
when both modifications are present. These observations,
when taken together, are consistent with a two-point (N-terminal
pThr and C-terminal pSer) binding model for the interactions
between AANAT and its 14-3-3-zeta partner. So, in the end,
both mechanisms postulated for increased AANAT activity,
improved catalytic efficiency (seen with sole pThr-31 modifica-
tion), and increased stability to proteolysis through binding
to 14-3-3-zeta (seen with sole pSer-205 phosphorylation and
with pThr-31/pSer-205 dual phosphorylation), appear to be
operative.
Conclusions
The (a,a-difluoro)methylene phosphonate analog of L-phospho-
serine isavailable throughchemistryemployingaM-CF2P(O)(OR)2
equivalent for PCF2-C bond formation via (i) triflate displace-
ment, (ii) carbonyl addition/reduction, or (iii) Cu-mediated alkene
addition. Within these approaches, absolute stereochemistry is
controlled by (i) starting from an appropriate chiral synthon-L-
serine, D-serine, or (R)-isopropylideneglycerol; (ii) utilizing a chiral
catalyst (lipase P) to desymmetrize an achiral intermediate; or (iii)
attaching a covalent chiral auxiliary for enantiomer resolution.
The pCF2-Ser mimic may be incorporated into peptides utilizing
SPPS, either for purposes of raising antibodies to specific pSer
modifications, or for installation a ‘‘constitutive pCF2-Ser modifi-
cation’’ into the native protein itself, using EPL methods. The
former application was used to firmly establish a connection
between p53 Ser-6 phosphorylation and DNA damage, and the
latter clarified the role of Ser-205 phosphorylation of AANAT
enzyme stabilization.
This technology adds an important element into the toolbox
available to the chemical biologist interested in studying sig-
nal transduction. Fundamental mechanistic questions relating
to kinase-mediated signal transduction in tumor suppression,
and in diurnal regulation of the time-keeping hormone, mela-
tonin, have been addressed. As the aforementioned studiesChemistry & Biology 16, September 25, 2009 ª2009 Elsevier Ltd All rights reserved 933
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Reviewdemonstrate, fluorinated phosphonate analogs of phospho-
amino acids provide for metabolically stable alternatives to the
native phospho-proteins, while retaining the ability to promote
protein-protein interactions that depend on that phosphoryla-
tion. This makes these unnatural amino acid analogs invaluable
tools for the dissection of such signal transduction pathways.
With the maturation of semisynthetic hapten construction,
expressed protein ligation and unnatural amino acid mutagen-
esis (Liu and Schultz, 1999; Xie and Schultz, 2005, 2006), and
the importance of kinase-mapping in the present day, the time
is ripe for expanded use of this isopolar phosphoserine mimic
in chemical biology.
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